GSK to Acquire Nuvalent for $10.6 Billion at 40% Premium
NUVL•British pharma giant GSK agreed to acquire developer Nuvalent for $10.6 billion in cash at $124 per share, representing a 40% premium to its pre-announcement closing price. The deal grants GSK three lung cancer assets including two late-stage tyrosine kinase inhibitors under FDA priority review with decisions due by year-end.
1. Deal Terms and Valuation
GSK will launch a tender offer within ten business days to acquire all outstanding Nuvalent shares for $124 each in an all-cash deal valuing the company at $10.6 billion, a 40% premium to its last closing price and 26% above its 30-day volume-weighted average.
2. Oncology Pipeline Assets
Nuvalent’s pipeline centers on two late-stage tyrosine kinase inhibitors—zidesamtinib (ROS1 inhibitor) and neladalkib (ALK inhibitor)—both under FDA priority review with target decision dates in September and November 2026, plus a Phase 1 HER2 inhibitor (NVL-330) and preclinical precision kinase programs.
3. Financing and Timeline
The transaction’s $9.4 billion net corporate investment will be funded primarily through new and existing debt facilities to maintain GSK’s investment-grade credit rating, with deal completion expected in the third quarter of 2026 pending regulatory clearances and majority tender acceptance.
4. Stock Market Reaction
Nuvalent stock surged 38.9% in premarket trading to a record high near $122.88 following the announcement, reversing earlier 12% declines this year, as short interest at 7% of float may drive further volatility during the tender period.
